Endo Health Solutions (ENDP) 8-K UBS Global Life Sciences Conference

drives us…

…is

our

passionate

pursuit

of

improving

patients’

lives.

What

ENDO PHARMACEUTICALS

UBS Global Life Sciences Conference

September 26, 2006

Exhibit 99.1

1

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Forward-Looking Statements

This

presentation

contains

forward-looking

statements,

within

the

meaning

of

Section

27A

of

the

Securities

Act

of

1933

and

Section

21E

of

the

Securities

Exchange

Act

of

1934,

as

amended,

that

are

based

on

management’s

beliefs

and

assumptions,

current

expectations,

estimates

and

projections.

These

statements

are

subject

to

risks

and

uncertainties

and,

therefore,

actual

results

may

differ

materially

from

those

expressed

or

implied

by

these

forward-looking

statements.

Forward-looking

statements

are

not

historical

facts

and

include

information

regarding

the

Company’s

possible

or

assumed

results

of

operations.

Also,

statements

or

expressions

that

are

preceded

by,

followed

by,

or

that

include,

the

words

“believes,”

“anticipates,”

“plans,”

“expects,”

“intends,”

“estimates”

or

similar

expressions

are

forward-looking

statements.

Endo’s

estimated

or

anticipated

future

results,

product

performance

or

other

non-historical

facts

are

forward-looking

and

reflect

Endo’s

current

perspective

on

existing

trends

and

information.

Many

of

the

factors

that

will

determine

the

Company’s

future

results

are

beyond

the

ability

of

the

Company

to

control

or

predict.

The

reader

should

not

rely

on

any

forward-looking

statement.

The

Company

undertakes

no

obligations

to

update

any

forward-looking

statements

whether

as

a

result

of

new

information,

future

events

or

otherwise.

None

of

the

development

products

in

the

Company’s

pipeline

have

been

established

as

safe

and

effective

by

the

FDA

or

approved

by

the

FDA.

Several

important

factors,

in

addition

to

the

specific

factors

discussed

in

connection

with

these

forward-looking

statements

individually,

could

affect

the

future

results

of

Endo

and

could

cause

those

results

to

differ

materially

from

those

expressed

in

the

forward-looking

statements

contained

herein.

Important

factors

that

may

affect

future

results

include,

but

are

not

limited

to:

the

Company’s

ability

to

successfully

develop,

commercialize

and

market

new

products;

results

of

clinical

trials

on

new

products;

competition

for

the

business

of

the

Company’s

branded

and

generic

products,

and

in

connection

with

the

Company’s

acquisition

of

rights

to

intellectual

property

assets;

market

acceptance

of

the

Company’s

future

products;

government

regulation

of

the

pharmaceutical

industry;

the

Company’s

dependence

on

a

small

number

of

products;

the

Company’s

dependence

on

outside

manufacturers

for

the

manufacture

of

its

products;

the

Company’s

dependence

on

third

parties

to

supply

raw

materials

and

to

provide

services

for

the

core

aspects

of

its

business;

new

regulatory

action

or

lawsuits

relating

to

the

Company’s

use

of

narcotics

in

most

of

its

core

products;

the

Company’s

exposure

to

product

liability

claims

and

product

recalls

and

the

possibility

that

the

Company

may

not

be

able

to

adequately

insure

itself;

the

Company’s

ability

to

protect

its

proprietary

technology;

the

Company’s

ability

to

successfully

implement

its

acquisition

strategy;

the

availability

of

controlled

substances

that

constitute

the

active

ingredients

of

some

of

the

Company’s

products

and

products

in

development;

the

availability

of

third-party

reimbursement

for

the

Company’s

products;

the

Company’s

dependence

on

sales

to

a

limited

number

of

large

pharmacy

chains

and

wholesale

drug

distributors

for

a

large

portion

of

its

total

net

sales;

and

other

risks

and

uncertainties

detailed

in

Endo’s

filings

with

the

Securities

and

Exchange

Commission,

including

its

Registration

Statement

on

Form

S-3

filed

with

the

SEC

on

March

21,

2006.

Readers

should

evaluate

any

statement

in

light

of

these

important

factors.

2

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Endo Profile

Fully

integrated

specialty

pharma

company

with

market

leadership

in

pain management; expanding into complementary therapeutic areas

Established

commercial capability:

Portfolio

of

branded

prescription

products

including

Lidoderm

®

,

Frova

®

, 

Percocet

®

and Synera™

Pipeline focused on delivering and executing:

Opana

®

ER and Opana

®

now FDA-approved; launched in mid-August 

Four additional products in mid-

to late-stage development

Strong cash flow and no debt

3

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Growth Strategy

Capitalize on established brand names and brand awareness through

focused marketing, promotional and educational efforts

Develop/acquire proprietary products in our therapeutic areas and

generic products with significant barriers to market entry

Build balanced, sustainable pipeline across development phases

Strengthen position in Pain Management and drive expansion into

complementary therapeutic areas such as:

Neurology

Perioperative Care

Supportive Care Oncology

4

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Selective focus on:

Generic Product Strategy

Niche therapeutic areas

Difficult-to-develop generics

Internally developed proprietary sustained-release technology

AB-rated MS Contin, OxyContin generics

Current marketed portfolio substantially consists of:

Oxycodone ER (until 12/31/06)

Endocet

®

Morphine Sulfate ER

5

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Purdue Litigation Settlement

Settlement of OxyContin patent case announced August 28, 2006

Endo to continue selling generic oxycodone extended-release

products until December 31, 2006

Endo released from all liability for patent infringement

Purdue’s lawsuit and Endo’s counterclaims against Purdue are

dismissed

Removes element of risk and allows us to focus on the ongoing

launch of Opana

®

ER and Opana

®

6

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Lidoderm

®

Profile

Topical patch launched in 1999

Covered by five Orange Book-

listed patents through 2015

First FDA-approved drug for the

treatment of the pain of post-

herpetic neuralgia, a form of

neuropathic pain

Provides analgesia (without

anesthesia) directly to the affected

nerves

7

©

2006 Endo Pharmaceuticals Inc.

What drives us…

*Represents

high

end

of

company

guidance

Lidoderm

®

Net Sales Growth

($ in millions)

$83

$178

$309

$419

$540

$0

$100

$200

$300

$400

$500

$600

2002

2003

2004

2005

2006*

8

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Frova

®

Profile

Triptan indicated for acute treatment of

migraine headaches in adults

Commercial strategy to implement

marketing, education and clinical plan to

differentiate Frova

®

in the marketplace

Low recurrence rate

Long half-life

Target specialty physician audience

Focus on neurologists, pain

management specialists

Leverage existing coverage of high

prescribers

Create advocacy base among thought

leaders

sNDA for indication of prophylaxis of

Menstrual Migraine filed 7/19/06

9

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Synera

TM

Profile

Topical, local anesthetic patch indicated

for use in children and adults to numb the

skin before various medical procedures;

e.g., blood draws or IV cannulation

Anticipated benefits include:

Fast onset of action

Ease of administration

Primary market is hospitalized pediatric

patients

Commercial shipments began 6/19/06

P&T Reviews to begin in earnest in Fall

Marketed by Endo’s 70-person hospital

sales force

Potential label expansion in pediatric

immunization (studies planned)

10

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Opana

®

ER and Opana

®

Review

11

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Opana

®

ER Profile

Broad

indication:

For

the

relief

of

moderate-to-severe

pain

in

patients

requiring continuous, around-the-clock opioid treatment for an

extended period of time

First time oxymorphone available in oral ER formulation

Proven efficacy in broad range of appropriate pain patients

Opioid-naïve/experienced

Chronic low back pain, osteoarthritis, cancer

Proven twice-daily dosing

Effective pain control demonstrated at stable dose for three months in

clinical

trials

underscores

durability

of

Opana

®

ER’s

analgesic

effect

Generally well-tolerated when titrated effectively*

*

Most

common

adverse

events

(>

10%)

in

trials

were

nausea,

constipation,

dizziness,

vomiting,

pruritus, somnolence, headache, increased sweating, and sedation

12

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Multiple Formulations

Opana

®

(immediate-release)

Indicated for relief of moderate-to-severe acute pain where the use

of an opioid is appropriate

Complementary to Opana

®

ER

Injectable formulation to be re-launched in the fall of 2006 under new

trade name

Multiple formulations offer physicians and patients an opioid with a

complete continuum of care

Gives physicians the capability to use the most appropriate formulation of

Opana

®

(ER, IR, injection) for each patient

13

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Opana

®

ER Commercial Strategy

Competes in $3.2 billion long-acting strong opioid market

Pricing comparable to other branded oral extended-release opioids

Sales force expansion to support new and existing brands

Added ~ 220 sales representatives

Entire

sales

force

of

590

detailing

physicians;

Opana

®

ER

and

Opana

®

in

primary position for 90% of calls

Maintaining overall detailing emphasis on Lidoderm

®

and Frova

®

Expanded sales forces promoting Opana ER/Opana in the primary

position to targeted audience of 68K experienced opioid prescribers

Represents approximately 80% of all opioid prescribers

Distribution to retail pharmacies continuing

Detailing began mid-August

Full marketing launch now underway with modified promotional materials

distributed to sales force

Voluntary DDMAC preview withdrawn

14

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Responsible Pain Management

Goal:

Focus on addressing appropriate use of opioid analgesics

and minimizing inherent risks of misuse, abuse and diversion

Risk Minimization Action Plan -

Endo has worked with outside experts, FDA

and DEA address appropriate labeling, distribution controls, proactive

surveillance, monitoring, and intervention, employee training, educational

initiatives on proper prescribing and clinical use of opioid analgesics

PROMISE™

initiative (Partnership for Responsible Opioid Management

through Information, Support and Education)

Consists

of

practical

information,

education

and

support

tools

--

all

focused on better ensuring the appropriate clinical use of opioid

analgesic medications. Website now live at www.endopromise.com.

15

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Significant Pipeline Opportunities

Transdermal

sufentanil

patch

(2)

Topical

ketoprofen

patch

(2)

Rapinyl™

(2)

Selected Endo Development Projects

sNDA filed July 19, 2006

Frova

®

(Menstrual Migraine)

(1)

Status

Filed

(1) 

Licensed marketing rights

(2)

Licensed marketing and development rights

16

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Frova

®

Clinical Development in MM

Two double-blind, placebo-controlled studies in Menstrual Migraine (“MM”)

prophylaxis; long-term open-label safety & tolerance study

Frova

®

taken for six days, starting two days prior to onset of expected MM

headache

Primary efficacy endpoint: reduction in the incidence of MM headache

(statistical and clinical significance achieved in both trials)

p<0.0001 to p < 0.01 (vs. placebo)

Secondary endpoints also achieved -

reduction in severity and duration of

MM headache

Results

of

first

Phase

III

efficacy

trial

published

in

July

2004

Neurology

Positive

confirmatory Phase III efficacy study announced May 8, 2006

sNDA accepted for review; PDUFA date of 5/19/07 confirmed

17

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Oral, fast-dissolving sublingual fentanyl tablet

Intended for the treatment of breakthrough

cancer pain

•

Expected to compete with Actiq and Fentora

Exclusive North American marketing and

development rights licensed from Orexo AB

Market Need Addressed:

Intended to compete in the market for

treatments of breakthrough cancer pain

Anticipated benefits include:

•

Fast onset of action

•

Enhanced absorption characteristics

•

Added convenience

Status:

Initiated Phase III clinical trials in Dec. 2005

Description / Indication:

Rapinyl

TM

18

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Topical patch intended for localized treatment

of acute pain associated with soft-tissue

injuries such as tendonitis/bursitis, joint

sprains or strains

Licensed marketing and development rights

from ProEthic in March 2005

Market Need Addressed:

Ketoprofen (NSAID) currently only available in

the U.S. in oral form

Will compete in the ~$2.5 billion soft-tissue

injury market primarily consisting of NSAIDs

and COX-IIs

Anticipated benefits include bypassing the

bloodstream, local/targeted pain control and

once-daily dosing

Status:

Three Phase III trials recently initiated in U.S.

Description / Indications:

Topical Ketoprofen Patch

19

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Transdermal patch intended for moderate-to-

severe chronic pain

Licensed marketing and development rights

from DURECT in March 2005

Market Need Addressed:

Will compete in the ~$3.2 billion strong opioid

market

Follow-on to Duragesic

Anticipated benefits include:

•

Convenience/compliance of seven-day dosing vs.

three days

•

Smaller patch -

20% the size of Duragesic

Status:

Phase I product characterization ongoing

Description / Indications:

Transdermal Sufentanil Patch

20

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Key Milestones for 2006

Launch

Opana

®

ER

and

Opana

®

Ongoing

File

sNDA

for

Frova

®

in

MM

prophylaxis                                  7/19/06

Initiate Phase III trials for topical ketoprofen patch

Late June

Launch Synera™

Ongoing

Advance pipeline development

Ongoing

Acquire / in-license opportunities in pain and

complementary areas such as neurology,

perioperative care and supportive care oncology

Ongoing

Building a solid platform for sustainable growth:

21

©

2006 Endo Pharmaceuticals Inc.

What drives us…

Summary

Fully

integrated

specialty

pharma

company

with

market

leadership

in

pain management; expanding into complementary therapeutic areas

Increasingly diverse revenue base

Well-developed commercial capability

Very broad and deep pain management pipeline

Strong financial condition

drives us…

…is

our

passionate

pursuit

of

improving

patients’

lives.

What

ENDO PHARMACEUTICALS

Nasdaq: ENDP